Literature DB >> 15494522

N-terminal residues of the chemotaxis inhibitory protein of Staphylococcus aureus are essential for blocking formylated peptide receptor but not C5a receptor.

Pieter-Jan Haas1, Carla J C de Haas, Wendy Kleibeuker, Miriam J J G Poppelier, Kok P M van Kessel, John A W Kruijtzer, Rob M J Liskamp, Jos A G van Strijp.   

Abstract

Staphylococcus aureus excretes a factor that specifically and simultaneously acts on the C5aR and the formylated peptide receptor (FPR). This chemotaxis inhibitory protein of S. aureus (CHIPS) blocks C5a- and fMLP-induced phagocyte activation and chemotaxis. Monoclonal anti-CHIPS Abs inhibit CHIPS activity against one receptor completely without affecting the other receptor, indicating that two distinct sites are responsible for both actions. A CHIPS-derived N-terminal 6 aa peptide is capable of mimicking the anti-FPR properties of CHIPS but has no effect on the C5aR. Synthetic peptides in which the first 6 aa are substituted individually for all other naturally occurring amino acids show that the first and third residue play an important role in blocking the FPR. Using an Escherichia coli expression system, we created mutant CHIPS proteins in which these amino acids are substituted. These mutant proteins have impaired or absent FPR- but still an intact C5aR-blocking activity, indicating that the loss of the FPR-blocking activity is not caused by any structural impairment. This identifies the first and third amino acid, both a phenylalanine, to be essential for CHIPS blocking the fMLP-induced activation of phagocytes. The unique properties of CHIPS to specifically inhibit the FPR with high affinity (kd=35.4 +/- 7.7 nM) could be an important new tool to further stimulate the fundamental research on the mechanisms underlying the FPR and its role in disease processes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15494522     DOI: 10.4049/jimmunol.173.9.5704

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

Review 1.  Enemy attraction: bacterial agonists for leukocyte chemotaxis receptors.

Authors:  Dominik Alexander Bloes; Dorothee Kretschmer; Andreas Peschel
Journal:  Nat Rev Microbiol       Date:  2014-12-15       Impact factor: 60.633

2.  The Sbi protein is a multifunctional immune evasion factor of Staphylococcus aureus.

Authors:  Emma Jane Smith; Livia Visai; Steven W Kerrigan; Pietro Speziale; Timothy J Foster
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

Review 3.  Neutrophils and Bacterial Immune Evasion.

Authors:  Scott D Kobayashi; Natalia Malachowa; Frank R DeLeo
Journal:  J Innate Immun       Date:  2018-04-11       Impact factor: 7.349

4.  Human formyl peptide receptor 2 senses highly pathogenic Staphylococcus aureus.

Authors:  Dorothee Kretschmer; Anne-Kathrin Gleske; Maren Rautenberg; Rong Wang; Martin Köberle; Erwin Bohn; Torsten Schöneberg; Marie-Joséphe Rabiet; Francois Boulay; Seymour J Klebanoff; Kok A van Kessel; Jos A van Strijp; Michael Otto; Andreas Peschel
Journal:  Cell Host Microbe       Date:  2010-06-25       Impact factor: 21.023

Review 5.  Gut microbiota, metabolites and host immunity.

Authors:  Michelle G Rooks; Wendy S Garrett
Journal:  Nat Rev Immunol       Date:  2016-05-27       Impact factor: 53.106

6.  Evasion of Toll-like receptor 2 activation by staphylococcal superantigen-like protein 3.

Authors:  B W Bardoel; R Vos; T Bouman; P C Aerts; J Bestebroer; E G Huizinga; T H C Brondijk; J A G van Strijp; C J C de Haas
Journal:  J Mol Med (Berl)       Date:  2012-06-20       Impact factor: 4.599

Review 7.  Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.

Authors:  Igor A Schepetkin; Andrei I Khlebnikov; Liliya N Kirpotina; Mark T Quinn
Journal:  Int Immunopharmacol       Date:  2015-09-15       Impact factor: 4.932

Review 8.  Anaphylatoxins: their role in bacterial infection and inflammation.

Authors:  Pieter-Jan Haas; Jos van Strijp
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 9.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

Review 10.  Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications.

Authors:  Alexander Laarman; Fin Milder; Jos van Strijp; Suzan Rooijakkers
Journal:  J Mol Med (Berl)       Date:  2010-02       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.